MoleculargeneticanalysisoftheNF2geneinyoungpatientswithunilateralvestibularschwannomasAMohyuddin,WJNeary,AWallace,CLWu,SPurcell,HReid,RTRamsden,ARead,GBlack,DGREvans.............................................................................................................................JMedGenet2002;39:315–322Neurofibromatosistype2(NF2)mustbesuspectedinpatientspresentingwithaunilateralvestibularschwannomaatayoungagewhoarethereforeattheoreticalriskofdevelopingbilateraldisease.Weidentified45patientsaged30yearsorlessattheonsetofsymptomsofaunilateralvestibularschwan-noma.MoleculargeneticanalysisoftheNF2genewascompletedonperipheralbloodsamplesinall45andon28tumoursamples.NopathogenicNF2mutationswereidentifiedinanyofthebloodsam-ples.NF2pointmutationswereidentifiedin21/28(75%)tumoursamplesandlossofheterozygosity(LOH)in21/28(75%)tumoursamples.Bothmutationalhitswereidentifiedin18/28(65%)tumoursamples.Inonemultilobulartumour,one(presumablyfirsthit)mutationwasconfirmedwhichwascom-montodifferentfociofthetumour,whilethesecondmutationaleventdifferedbetweenfoci.ThemolecularfindingsinthispatientwereconsistentwithsomaticmosaicismforNF2andtheclinicaldiag-nosiswasconfirmedwiththepresenceoftwomeningiomasonafollowupMRIscan.AfurtherpatientdevelopedacontralateralvestibularschwannomaonafollowupMRIscaninwhomneitherofthetrun-catingmutationsinthevestibularschwannomawerepresentinblood.Itisimportantwhencounsellingpatientswithunilateralvestibularschwannomastoidentify(1)thoseatriskofbilateraldisease,(2)thoseatriskofdevelopingothertumours,and(3)otherfamilymembersatriskofdevelopingNF2.ComparingtumourandbloodDNAcannotexcludemosaicismintheindexcaseandcannot,therefore,beusedtopredictthoseatriskofdevelopingfurthertumours.However,identificationofbothmutationsoronemutationplusLOHinthetumourandexclusionofthosemuta-tionsinthebloodsamplesofthesibsoroffspringoftheaffectedcasemaybesufficienttorenderfur-therscreeningunnecessaryintheserelatives.Themajority(>95%)ofvestibularschwannomasaresporadicandunilateralandpresentinthefourthandﬁfthdecades.12Inthesecasestheyhavenobroaderclinicalimplicationsforeitherpatientorfamily.Whenbilateral,thetumours23representamanifestationofneuroﬁbromatosistypeII(NF2),anautosomaldominantcondition,whichhasapopulationincidenceof1in33000to1in40000.4ThehallmarkofNF2isthedevelopmentinthesecondandthirddecadesofbilateralvestibularschwannomas.NF2isalsocharacterisedbyapredispositiontothedevelopmentofothertumoursofthecentralandperipheralnervoussystem,includ-ingmeningiomas,gliomas,andspinalschwannomas/neuroﬁbromas.5DiagnosticcriteriaforNF2wereagreedbytheNationalInstitutesofHealthConsensusDevelopmentConfer-encein1987(table1A)andadditionalcriteriadescribedbyEvansetal6in1992(table1B).Thereisevidencetosuggestthatpatientsaged30yearsorlessattheonsetofsymptomsofaunilateralvestibularschwannomaareathighriskofbeingaffectedwithavariantformofNF2.78Approximately10-18%ofNF2casespresentinitiallywithaunilateralvestibularschwannomaratherthanwithbilateraltumours.However,thisisusuallyaccompaniedorprecededbyotherfeaturessuchasmeningiomas,skintumours,symptomaticspinaltumours,orafamilyhistoryofNF2.69–11Vestibularschwannomasarisefromtheinactivationofmerlin,theproteinproductoftheNF2tumoursuppressorgene,whichregulatesSchwanncellgrowth.Sporadictumoursdifferfrominheritedtumoursinthattheﬁrstmutationalhitisacquiredandmaybepresentinmosaicform.SubjectswhoaremosaicforaNF2mutationareatriskoftransmittingthemutationtotheiroffspringifitispresentinthegonads.12TheNF2genewasisolatedin1993,1314afterlinkagestudieshadassignedthegenetochromosome22.15GermlinemutationshavebeenreportedbyseveralworkersinlargeseriesofpatientsaffectedwithNF2.16–19However,onlyabout40%ofdenovocasesofNF2haveanidentiﬁablemutationinlymphocyteDNA.1220AspatientswhopresentwithaunilateralTable1DiagnosticcriteriaforNF2AdiagnosisofNF2ismadeinapatientwhohas(NIHcriteria,1987):BilateralvestibularschwannomasORfamilyhistoryofNF2PLUSunilateralvestibularschwannomaORanytwoof:meningioma,glioma,neurofibroma,schwannoma,posteriorsubcapsularlenticularopacitiesAdiagnosisofNF2canalsobemadeinapatientwhohas(Evansetal6):UnilateralvestibularschwannomaPLUSanytwoof:meningioma,glioma,neurofibroma,schwannoma,posteriorsubcapsularlenticularopacitiesORmultiplemeningiomas(2ormore)PLUSunilateralvestibularschwannomaORanytwoof:glioma,neurofibroma,schwannoma,cataractSeeendofarticleforauthors’affiliations.......................Correspondenceto:MrAMohyuddin,FRCS,UniversityDepartmentofMedicalGeneticsandRegionalGeneticServices,StMary’sHospital,HathersageRoad,ManchesterM13OJH,UK;atai_1999@yahoo.comRevisedversionreceived20February2002Acceptedforpublication26February2002.......................315www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from vestibularschwannomaatayoungageareatriskofdevelop-ingbilateraldisease,itwouldbevaluabletoidentifythosewhorequirefurtherscreeningforNF2tumours.Therearealsoimplicationsforotherfamilymemberswhocouldrequiretumoursurveillanceandgeneticcounselling.Wehavepreviouslyproposedastrategy,basedontheanaly-sisoftumourDNA,fordistinguishingfamilialandsporadiccasesoftumourscausedbytheinactivationofatumoursup-pressorgene.21Wehavenowappliedthisstrategybycompletelyanalysingtumourmaterialfrom28of45youngpatientswithanapparentlyisolatedunilateralvestibularschwannomatoestablishwhetherthemutationspresentinthetumouraretheresultofagermlinemutationorarelikelytobetheresultofsomaticevents.METHODSPatientsPatientswhopresentedwiththeonsetofﬁrstsymptomsofaunilateralvestibularschwannomawhenaged30yearsorlesswereincludedinthisstudy.Allpatientswhohadafamilyhis-toryofanyneurogenictumourswereexcludedfromthestudy.AllpatientswhowereincludedinthisstudywereexaminedclinicallyforanycutaneousfeaturesofNF2.Patientsunderwentophthalmologicalexaminationtolookforjuvenileposteriorsubcapsularlenticularopacitiesandcorticalopaci-ties.Aneuro-otologicalexamination,whichincludedpuretoneaudiometry,stapedialreﬂexmeasurement,andauditorybrainstemresponsetesting,wasalsoperformed.Magneticresonanceimagingwithgadolinium-DTPAenhancementwasusedtoassessallpatientsafter1990,sothatacontralateralvestibularschwannomaoranyothercranialtumourcouldbeexcluded.Atotalof689patientswhopresentedwithaunilateralves-tibularschwannomawereseenattheneuro-otologyclinicbetweenJanuary1978andDecember1998.Inanearlierstudyweselected93of407ofthesepatientsongeographicalcrite-riaforadetailedstudyofpatientsandfamilieswithaunilat-eralvestibularschwannoma.7Sixpatientswererecruitedfromthisretrospectiveseries.Theremainderoftheserieswererecruitedfrompatientsmeetingtheinclusioncriteria.ThirtypatientswhometthesecriteriafromourhospitalserieswerestudiedbylookingatboththeirclinicalfeaturesandanalysingforNF2mutationsinbothtumourandblood.Theremaining15patientsreferredfromothercentreswithanapparentlyisolatedunilateralvestibularwereanalysedonbloodalone.DNAextractionDNAwasextractedfrombloodandtumour(freshandparaf-ﬁnﬁxed)specimensfrom30outof45cases.DNAwasavail-ableonlyfrombloodintheremaining15samples.GenomicDNAwasextractedfromperipheralbloodlymphocytesusingstandardprocedures.DNAwaspreparedfromfreshandparafﬁnembeddedtumourspecimensaccordingtothemeth-odsdescribedbyWuetal.21Onetumour(case10)appearedtobemultifocalatsurgeryandseparatefociwerebiopsiedandprocessedseparately.MoleculargeneticanalysisGenomicandtumourDNAsampleswereampliﬁedforall17exonsoftheNF2gene.TheprimersforthemajorityofexonsusedwerethosedescribedbyMereletal.18However,theprimerpairsforexons1,2,and3alongwiththereverseexon6andforwardexon8primerwereredesignedtoincludethewholeexonandsplicedonor/acceptorsites(table2).SSCPheteroduplexanalysisSSCP/heteroduplexanalysiswascarriedouton32cmlong8%(49:1acrylamide:bisacrylamideratio)nativepolyacrylamidegelsrunat360Vconstantvoltageforapproximately16hoursat4°C.SSCPandheteroduplexeswerethenvisualisedbysilverstaining.22SamplesthatgaverisetoSSCP/heteroduplexshifts,whichwerepresentatlowlevelsonsilverstainedSSCP/HA(minorityalleles),werereampliﬁedandalargerquantityofthesamplewasloadedontoasecondSSCP/HAgel.Thegelwassubjectedtosilverstainingaspreviouslyexceptthatthefourthsolutionwasreplacedwith50mmol/lEDTA.Thegelsliceswerebrieﬂyrinsedin50µlsterilewaterandDNAwaselutedbycrushingandsoakingovernightin50µlofsterilewater.TheminorityallelesisolatedfromthegelwerethenreampliﬁedbyPCRfromtheeluate.DNAproductspurificationandsequencingThesampleswerepuriﬁedbeforesequencingusingCentricon100columns.A40µlPCRreactionwasaddedto2mlofster-ilewateronthecolumnsaccordingtothemanufacturer’sinstructions.ThepuriﬁedDNAproductswerethenvisualisedona2.5%agarosegeltocheckforrecovery.DNAsequencingreactionswerecarriedoutinbothforwardandreverseorien-tationsforeachsampleusingBigDyeTerminatorv20readyreactionkits.ElectrophoresisandﬂuorescentdetectionofthesequencingreactionswascarriedoutonanAppliedBiosys-tems377Asequencerwith48cmwelltoreadplates.Lossofheterozyosity(LOH)studiesLOHwasdetectedusingacombinationoffourmicrosatellitemarkers:D22S275,23NF2CA3,24D22S268,25andD22S280.26NF2CA3islocatedwithinintron1oftheNF2genewhereasD22S275,D22S268,andD22S280arealltightlylinkedtotheNF2gene.27FormarkersD22S275,NF2CA3,andD22S268.LOHwasdeterminedusingﬂuorescentlylabelledPCRproducts,thelymphocyteandtumourDNApairsbeingampli-ﬁedandsubjectedtosimultaneouselectrophoreticanalysistocomparelymphocyteandtumourDNAusingtheGenescanv2.1.1fragmentanalysisprogram.AdiminutioninrelativeallelesignalstrengthbetweenlymphocyteandtumourDNAofmorethan30%wastakenasindicativeofLOH.ForthemarkerD22S280,LOHwasdeterminedbycomparisonoflymphocyteandtumourDNA.PCRampliﬁcationswereelectrophoresedonnon-denaturinggelsandvisualisedbysil-verstaining.RESULTSThemeanageofonsetofsymptomsinthe30patientswhereblood/tumouranalysiswascarriedoutwas23.1years.Thiscomparedwith47.5yearsforourhospitalbasedseriesof689patientswithunilateralVS.Theaveragedurationfromageofonsetoftheﬁrstsymptomstoageatwhichthepatientswerediagnosedasaffectedwithaunilateralvestibularschwan-nomawas3.7years.Therewere16femalesand14males.TheTable2RedesignedprimersforamplificationofNF2exonsNameForwardprimer(5¢ﬁ3¢)Reverseprimer(5¢ﬁ3¢)NF2Ex1tggccctgaggcctgtgcagcaacgagaacctctcgagcttccacNF2Ex2tgtccttccccattggtttgcagtttcatcgagttctagccNF2Ex3gcttctttgagggtagcacaggtcaactctgaggccaactctgcaNF2Ex6–cccataaaggaatgtaaaccaacNF2Ex8gagcctcagctggcgcttac–316Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from clinicaldetailsaresummarisedintable3.Noneofthepatientshadafamilyhistoryofvestibularschwannomaorothercranialtumours.Caféaulaitpatcheswerefoundoncutaneousexaminationinsixseparatecases,withonecase(case23)havingﬁvecaféaulaitpatches.Subcutaneouslumpswerefoundintwocases(cases9and20),butneitherhadbeenbiopsiedasthesewerenotsuspectedclinicallytobeschwannoma.Allthepatientsselectedforthestudywerefollowedupwithregularclinical,audiologicalandradiologicalexamination.Onepatient(case10)wassubsequentlyalsofoundtohavetwoipsilateralcranialmeningiomasonfollowupMRIscan.Afurtherpatient(case26)developedacontralateralvestibularschwannomathreeandahalfyearsafterundergoingsurgeryforaunilateralves-tibularschwannoma.Twenty-twooutof689patientsinthehospitalserieshadaunilateralvestibularschwannomaoninitialcranialscan,buthadotherNF2featuresorhadaunilateralvestibularschwannomaandafamilyhistory;13ofthesefulﬁlledNF2criteriaandsevenpresentedatlessthan30yearsofage.Allwereexcludedfromthepresentstudypopu-lation.Allother28patientsremainwellwithnocranialtumoursonfollowupMRIscanthreeto20yearsafterinitialdiagnosis.MoleculargeneticanalysisAnalysisoflymphocyteDNAForty-ﬁvepatientsweretestedforgermlinemutationsfromlymphocyteDNAandtwoofthemwerefoundtohavesequencechanges.Themutationsidentiﬁedinthebloodsam-plesofthesetwopatients(cases2and9)wereconsideredtobenon-pathogenicNF2polymorphisms.Aninframedeletion332-4wasidentiﬁedinbloodfromonepatient(case9),whichwassubsequentlyfoundinhisunaffectedmother(ﬁg1A),andwasthoughtnottobepathogenic.Twopathogenicmuta-tionalhitswereidentiﬁedinthetumoursamplefromthepatient.AtruncatingmutationwasidentiﬁedwhichwasnotdetectableinthelymphocyteDNAsample(ﬁg1B).ThetumouralsoshowedclearevidenceofLOHwithmarkersD22S275andD22S268(ﬁg1C).Theallelelostinthetumouristhatcontainingtheinframe3bpdeletionsincethesignalfromthisisdiminished.Asaconsequence,thetruncatingmutationispresumablyontheotherallele.Thepatient’smotherhasnoclinicalfeaturesofNF2,andMRIwithgadolinium-DTPAenhancementshowednoevidenceofvestibularschwannomasorothercranialtumours.Asynony-mouscodonsubstitutionwasalsoidentiﬁedinonefurtherpatient(case2).AnalysisoftumourDNATumoursof28patientswereanalysedforpointmutationsthroughoutthewholecodingsequenceoftheNF2gene.Theresultsoftheanalysisareshownintable4.Pointmutationswereidentiﬁedin21/28tumoursamples(75%).Lossofheterozygosity(LOH)waspresentin21/28tumoursamples(75%).Twomutationalhitswereidentiﬁedin18/28tumours(65%)andasinglemutationaleventestab-lishedin7/28(24%).Inthreeoutof28(11%)tumours,nomutationaleventwasfound.In21/28tumoursamplesthereweretruncatingmutations,withframeshiftdeletionsoccur-ringin11outof21(52%)andnonsensemutationsineightoutof21(38%).Twotumourshadsplicesitemutations(9.5%).Twopatients(cases10and26)havesubsequentlydevelopedsecondNF2relatedtumours.Case10,inwhomaclinicaldiagnosisofNF2hassincebeenconﬁrmedbythepresenceofcranialmeningiomas,developedaunilateralmul-tilobularvestibularschwannoma.AmissensemutationVal219>Metwasconﬁrmedtobecommontotwodifferentfociofthetumour.Intheﬁrstfocus,asecondhitwasnotidentiﬁed.Inthesecondfocus,twofurtherpathogenicmuta-tionswerefoundasminorityalleles(ﬁg2A-C).ThissameTable3Clinicalfeaturesof30youngpatientsdiagnosedwithaunilateralvestibularschwannomaCaseSexAgeatfirstsymptoms(y)Ageatdiagnosis(y)OtherNF2featuresFamilyhistoryConclusionafterDNAstudies1M1826NilNilSporadic2F1923NilNilSporadic3F2427NilNilSporadic4F1922CALpatchesNilSporadic5M1737NilNilSporadic6F2934NilNilUndetermined7F2939NilNilSporadic8M2931NilNilUndetermined9M2529OneCAL:lumpanteriorthighNilSporadic10F2529*2meningiomasNilMosaic11F1820NilNilSporadic12M2526NilNilSporadic13F1724NilNilUndetermined14M2427OneCALpatchNilI6/17exonsanalysed15F2021NilNilSporadic16M1821NilNilSporadic17M3031NilNilUndetermined18M2324OneCALpatchNil5/17exonsanalysed19F1821NilNilInsufficientmaterialfortumouranalysis20M2529OneSClumpNilSporadic21M2224NilNilSporadic22F2125NilNilSporadic23F26285CALpatchesNilSporadic24F3032NilNilSporadic25F2324NilNilSporadic26F26283CaLpatchesandcontralateralVS*NilMosaic27F2629NilNilSporadic28M2930NilNilSporadic29M2426NilNilSporadic30M1416NilNilSporadicCAL=caféaulait.SC=subcutaneous.*OnlyafterinitialassesmentofMRI;sporadicstatusisassumed,althoughmosaicismcannotbeexcluded.PotentialofNF2inpatientswithearlyonsettumours317www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from biopsyspecimenthatshowedthreeapparentmutationsalsoshowedevidenceofLOH(ﬁg2D).However,themissensemutationwasthepredominantalleleinthisbiopsyspecimen.IntheabsenceofamutationinlymphocyteDNAfromthispatient,theﬁndingswerestronglysuggestiveofmosaicism.Thedaughterofthispatient,whowasthereforedeﬁnedasbeingmosaicforNF2,hassincebeenexcludedascarryingtheprimarymutation,aswellasthesecondarymutationsthatwereidentiﬁedinhermother’stumour;shehasthereforebeenexcludedfromtumoursurveillance.Case26hasgoneontodevelopacontralateralvestibularschwannomathatwasnotdetectedontheoriginalMRIscan.ThispatientcarriedtwotruncatingmutationsinthesameexonintumourDNA;thesecondsplicingmutation(table4)wasinitiallyoverlookedasamutationhadalreadybeeniden-tiﬁedinthatexon.Noabnormalitywasdetectedinherperipheralblood.ShestillhasnootherfeaturesofNF2includingaclearspinalMRIscan.Afurtherattempttoﬁndagermlinemutationwasundertakeninthe10outof28patientsinwhomtwoFigure1Molecularanalysisofcase9.(A)SSCP/HAofexon3.LymphocyteDNAfromboththepatientandhisparentsareindicatedbythepedigree.BoththepatientandhisunaffectedmotherclearlyhaveaSSCPandheteroduplexshift;onsequencingthiswasfoundtobeaninframedeletionofaminoacidresidueGlu112.Thetumoursamplefromthepatient(T)alsoclearlyhasDglu112,althoughtheNF2allelecarryingDglu112showsdiminutionofsignalindicatingalleleloss.(B)SSCP/HAanalysisofexon5.Thetumourfromcase9hasaSSCPandheteroduplexshiftthatisnotpresentwithinhislymphocyteDNAsample(L);onsequencingthisshiftwasfoundtobeanonsensemutation(Tyr153>Stop,nt459>G).TheshiftoriginatingfromTyr>Stopisatapproximatelythesamelevelasthenormalsignal.(C)LOHanalysis.ComparisonoflymphocyteandtumourDNAwiththetwocloselylinkedmicrosatellitemarkersD22S275andD22S268.Anallelewithbothmarkerscanbeseenatmarkedlyreducedintensityindicatingallelelossinthetumourtissue.ThissamplewasnotinformativefortheintragenicmarkerNF2CA3.Mwt=molecularweightmarker.NC=normalcontrol.900150160D22S275ABCMWtLTNCNCMWtTNC1701801908007006005004003002001000Tumour+180016001400120010008006004002000Lymphocytes720150160D22S268170180190640560480400320240160800Tumour+36032028024020016012080400Lymphocytes318Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from mutationalhitswerenotestablishedinthetumour.BloodDNAwasanalysedbyFISHanalysiswithprobesLL96C10andLL4D7(courtesyofJanDumanski)anddosagePCRforexons1,4,8,and15.Nofurthermutationswereidentiﬁed.Nochil-drenoftheunilateralvestibularschwannomaserieshasdevelopedNF2.Thedaughterofthemosaicpatient(case10)hasbeenexcludedfromcarryingthemutationsidentiﬁedinhermother’stumour.Table4SSCP/HAanalysisandLOHstudiesonlymphocyteandtumoursamplesfrom30youngpatientswithaunilateralvestibularschwannomaCaseTissueSSCP/HALOHanalysisMutationClassD22S275NF2CA3D22S268D22S2801L-ve–T1080DGFLOHLOHLOH–2L465C>TSYTD757-795(DLys253>Ser265)IF–LOH–LOH3L-ve–T1443C>G(Tyr481>Stop)NLOHULOH–4L-ve–T459C>A(Tyr153>Stop)N–LOH–N5L-ve–T448-1g>tSP–LOH––6L-ve–T1228C>T(Gln433>Stop)NUUN–7L-ve–T970C>T(Gln324>Stop)NLOHULOH–8L-ve–T-ve–LOHULOH–9LD332-334(DGlu112)IFT459C>G(Tyr153>Stop)NLOHULOH–10L-ve–T1169C>T(Arg57>Stop)NLOHUU–655G>A(Val219>Met)M1600DCFT2655G>A(Val219>Met)MNUU–11L-ve–T1514DTGF–LOH––12L-ve–T479DGFLOHULOH–13L-ve–TD171-216FNRNN–14L-ve–T-vefor16/17exons*––LOH––15L-ve–T1513DCTGTFLOHUU–16L-ve–T169C>T(Arg57>Stop)N–LOH––17L-ve–T-ve––LOH––18L-ve–T-vefor5/17exons*–––––19L-ve–Tinsufficientmaterial–––––20L-ve–T1621DGF–LOH––21L-ve–Tnt1366C>T(Glyn456>stop)––LOH––22L-ve–T447+2t>cSPNUU–23L-ve–T653DGF–LOH––24L-ve–T54insAF–LOH––25L-ve–T-ve––LOH––26L-ve–T737DCF–N––nt810g>aSP27L-ve–T-ve––N––28L-ve–T-ve––N––29L-ve–T265insGF–LOH––30L-ve–T-ve–UUU–Tissue:L=lymphocyteDNA,T=tumourDNA.SSCP/HA:F=frameshift,SP=splicesite,N=nonsense,M=missense,IF=inframedeletion,SY=synonymouscodonsubstitution,–=nomutation,*=insufficientmaterialforcompleteanalysis.LOHanalysis:LOH=lossofheterozygosity,U=uninformative,N=nolossofheterozygosity,NR=noresult,–=nottested.PotentialofNF2inpatientswithearlyonsettumours319www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from DISCUSSIONVestibularschwannomasarisefromtheinactivationoftheNF2tumoursuppressorgene,whichregulatesschwanncellgrowth.Vestibularschwannomasoriginateinthedistalneuri-lemmalportionofthevestibularnerveatorclosetotheneurilemmal-neuroglialjunction.28Theyarebenignneo-plasmsoftheSchwanncellsheath.Thisstudyhasconﬁrmedourrecentworkwhichshowsthatonlyaverysmallnumberofsubjectswithanisolatedunilat-eralVSarelikelytoharbouragermlinemutationintheNF2geneorgoontodevelopbilateraldisease.11Outofthe45youngunilateralvestibularschwannomapatientsthoughttobeathighriskofdevelopingNF2,onlytwohadidentiﬁablesequencevariationsinbloodsamples(cases2and9).Bothwereconsideredtobenon-pathogenicpolymorphisms.Oneofthetwo(case9)hadanidentiﬁablesequencevariation(lossofaglutamineatposition112intheNterminalregion),which,afterfurtherexaminationofthefamilyandmolecularanaly-sisofhistumour,wasconﬁrmedtorepresentararepolymor-phism.Thisaminoacidchangewasonthesameallelethatshowedlossofheterozygosityandwaspresentinthepatient’smother,whohadnoevidenceofcranialtumoursonMRIaged59years.Oneofthesesubjects,case10,ismosaicforavalinetomethioninemissensemutationatposition219,whichispredictedtoaffectthenormalconformationofthealphaheli-caldomain.Giventhatthischangewasdenovo(notpresentingermlineDNA)andwasconﬁrmedintwoseparatefocioftumour,itishighlylikelytobepathogenic.Theresultsfromonebiopsyfromthemultifocaltumourinthiscaseappearstoshowfourseparatehits,includingLOH.Itislikelythatthisbiopsyhastakenmaterialfromthreeseparatefocioftumour;inthiscasethepredominantallelecontainsthemissensemutationpresentinallthreefoci.ThepresenceofmultifocaltumoursinNF2haspreviouslybeendescribedatthemacroscopiclevel.1029Unliketrulysporadicunilateraltumours,theyoftenappearasa“bunchofgrapes”aroundthevestibularnerveandmayaccountforsomeofthepoorersurgicalandradiotherapyresultsinNF2.10Thisistheﬁrsttimetoourknowledgethatthemultifocalityofaves-tibularschwannomahasbeenprovenatthemolecularlevel.Afurtherlessonisseenincase26wheretwomutationsweredetectedinthesameexontoaccountforaSSCPshift,indicat-ingthattheentiresequenceoftheexonshouldbeexaminedinatumourspecimenwheretwohitsarepossible.Itispossiblethatapredisposingmutationcouldbepresentinthe10patientsinwhomtwohitswerenotestablished.Zucman-Rossietal30havedescribedamutationscreeningstrategy,whichhasraisedtheefﬁciencyofmutationdetectioninNF2patientsto84%intheirseries.OurcombinedstrategyFigure2Molecularanalysisofcase10.(A)SSCP/HAanalysisofexon2.Thefirstsamplefromthetumour(T1)hasaweakSSCPandheteroduplexshiftthatwassequencedasanonsensemutation(Arg57>Stop,nt169c>T).Thisshiftisabsentfromthepatient’slymphocyteDNA(L)andfromthesecondtumoursample(T2).Amutationcontrolhasalsobeenrunfromapatientwhocarriesthesamemutationin50%oftheirlymphocytes(MutC).(B)SSCP/HAanalysisofexon7.Bothtumoursamplesfromcase10(T1andT2)havethesameshiftwhichwassequencedasamissensemutation(Val219>Met,nt655G>A).TheshiftcorrespondingtoVal219>Metisnotpresentatdetectablelevelsinthepatient’slymphocyteDNAsample(L).ThemutationappearstobepresentatahigherlevelinsampleT1.(C)SSCP/HAanalysisofexon15.Averyweakheteroduplexshiftwasobservedinthefirsttumoursample(T1)whichwassequencedas1600DC.Thisshiftwasnotobservedatdetectablelevelsineitherthepatient’slymphocyteDNA(L)orthesecondtumoursample(T2).(D)LOHanalysis.ComparisonoflymphocyteDNAandthetwotumourDNAsampleswiththeintragenicmicrosatellitemarkerNF2CA3.Thefirsttumoursampleshowssignificantbutnotcompletelossofoneallele(arrowed).Therewasnodetectableallelelossinthesecondtumoursample.NC=normalcontrol.150160BACDLT2Mut CNCT1LT2NCT1LT2NCT11701802001902700240021001800150012009006003000Lymphocytes2702402101801501209060300Tumour 1180016001400120010008005004002000Tumour 2+320Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from ofSSCP,FISH,anddosagePCRiscapableofdetectingmorethan90percentofmutationsintheNF2families(unpublisheddatainsecondgeneration).Thestandardmuta-tiondetectiontechniquessuchassinglestrandconformationpolymorphism(SSCP)analysisordenaturinggradientgelelectrophoresis,however,donotdetectmutationsineveryclassicallyaffectedpatient.Also,thesensitivityofSSCPtodetectmutationshasbeenreportedinvariousseriestovaryfrom35-66%.17183132Inpatientswithunilateraltumoursorwithoutafamilyhis-tory,failuretodetectamutationinDNAfromthepatient’sbloodcannotbeusedasameansofanalysingNF2;failurecouldbeeitherbecauseoflowlevelsofmosaicismoramuta-tionundetectedbyourscreeningprotocol.In65%(18/28)oftheseapparentlyhighrisksubjects,ithasbeenpossibletoexcludethepresenceofapathogenicmutationinmorethan10%oflymphocytesbyidentifyingbothhitsinthetumourwithnonebeingdetectableinblood.MosaicisminNF2isnowawelldescribedentity.1220SubjectswhofulﬁlthemodiﬁedNF2diagnosticcriteria(table1B),suchascase10,arejustaslikelytohaveanidentiﬁableNF2mutation12assporadicpatientswhofulﬁltheclassicalcriteriaofbilateralvestibularschwannomas.However,somepatientslikecase10andapre-viouslydescribedcase21havemosaicism,whichappearstobepredominantlyononeside.Whileitis,ofcourse,possiblethatcase10mayeventuallydevelopbilateraldisease,thismaynotbyanymeansbecertain.Thispatternmaythereforebemoreakintopreviousreportsofsegmentaldiseaseinneuroﬁ-bromatosistype1.33Thedatapresentedhere,inconjunctionwiththosefromaretrospectiveanalysisofover300NF2patients,11suggestthatwhileupto18%ofNF2patientsmaypresentinitiallywithaunilateralvestibularschwannoma,thegreatmajorityofthesewillhaveotherfeaturesofNF2atthetimeofdiagnosisoftheireighthnervetumourorhaveapositivefamilyhistoryofNF2.Ofthetwosubjects(cases10and26)inthisstudywhosofarhavegoneontodevelopNF2,one(case10)hadpredictablefeaturesinhertumour,andwhileitisimpossibletoruleoutmosaicisminanyoftheotherpatients,itisunlikelythattheotherswilldevelopNF2.Indeed,onlyﬁvepatientsofourpre-viousseriesofover300NF2patientspresentedwithasporadicunilateralvestibularschwannoma.Thereforeinpatientswithanapparentlysporadicunilateralvestibularschwannoma,iftherearenoNF2relateddiagnosticclinicalfeaturesandnofamilyhistoryofNF2relatedproblems,itishighlyunlikelythattheywilldevelopbilateraldiseaseorpassonapathogenicNF2mutationtotheiroffspring,eveniftheypresentataveryyoungage.Intheseyoungpatients,asmosaicismcannotbeexcluded,afollowupMRIscanofthecraniumisindicatedatﬁveand10yearsafterdiagnosis.34Furthermutationalanalysisofablood-tumourpairwillreduceanyfurthertheoreticalrisk.Oncecompleted,offspringcanbetestedforNF2mutationsidentiﬁedintheparentaltumourinordertoaccountforthesmallresidualriskofgerminalmosaicism.ACKNOWLEDGEMENTSTheﬁrsttwoauthorscontributedjointlytothiswork.WewishtothanktheNHSExecutiveNorthWestandtheBrendaThornleyTrustfortheirﬁnancialsupportforthisresearchworkandMrsCeliaWors-leyforpreparingparafﬁnsectionsoftumoursamples.GBisaWellcomeClinicianScientistFellow......................Authors’affiliationsAMohyuddin,AWallace,CLWu,SPurcell,ARead,GBlack,DGREvans,UniversityDepartmentofMedicalGeneticsandRegionalGeneticServices,StMary’sHospital,HathersageRoad,ManchesterM13OJH,UKWJNeary,WarringtonCommunityHealthCare(NHS)Trust,ChildandFamilyServicesUnit,GuardianHouse,GuardianStreet,WarringtonWA5ITP,UKHReid,DepartmentofPathology,ManchesterRoyalInfirmary,OxfordRoad,ManchesterM139WL,UKREFERENCES1PoolJL,PavaAA,eds.Theearlydiagnosisandtreatmentofacousticnervetumors.1sted.Springfield,Illinois:CCThomas,1957:22.2PoolJL,PavaAA,GreenfieldEC.Acousticnervetumors-earlydiagnosisandtreatment.2nded.Springfield,Illinois:CCThomas,1970:23.3RevillaAG.Neurinomasofthecerebellopontilerecess:aclinicalstudyof160casesincludingoperativemortalityandendresults.BullJohnsHopkinsHosp1947;80:254-7.4EvansDGR,HusonSM,DonnaiD,NearyWJ,BlairV,TeareD,NewtonV,StrachanT,RamsdenRT,HarrisR.Ageneticstudyoftype2neurofibromatosisintheUK.I.Prevalence,mutationrate,fitness,andconfirmationofmaternaltransmissioneffectonseverity.JMedGenet1992;29:841-6.5MartuzaRL,EldridgeR.Neurofibromatosis2(bilateralacousticneurofibromatosis).NEnglJMed1988;318:684-8.6EvansDGR,HusonSM,DonnaiD,NearyWJ,BlairV,NewtonV,HarrisR.Aclinicalstudyoftype2neurofibromatosis.QJMed1992;84:603-18.7NearyWJ,NewtonVE,Laoide-KempSN,RamsdenRT,GriffithG,EvansDGR,HarrisR,StrachanT.Aclinicalgeneticandaudiologicalstudyofpatientsandfamilieswithunilateralvestibularschwannomas.1.Clinicalfeaturesofneurofibromatosisinpatientswithunilateralvestibularschwannomas.JLaryngolOtol1996;110:634-40.8ParryDM,EldridgeR.Neurofibromatosis2:groupsathighrisk.In:ProceedingsoftheFirstInternationalConferenceonAcousticNeuroma.Copenhagen:KuglerPublications,1992:811-14.9ParryDM,EldridgeR,Kaiser-KupferMI,BouzasEA,PikusA,PatronasN.Neurofibromatosis2(NF2):clinicalcharacteristicsof63affectedindividualsandclinicalevidenceforheterogeneity.AmJMedGenet1994;52:450-61.10EvansDGR,RamsdenRT,HusonSM,HarrisR,LyeR,KingTT.Type2neurofibromatosis:theneedforsupraregionalcare?JLaryngolOtol1993;107:401-6.11EvansDGR,LyeR,NearyWJ,BlackG,StrachanT,WallaceA,RamsdenRT.Probabilityofbilateraldiseaseinpeoplepresentingwithaunilateralvestibularschwannoma.JNeurolNeurosurgPsychiatry1999;66:764-67.12EvansDGR,WallaceA,WuCL,TruemanL,RamsdenRT,StrachanT.Somaticmosaicism:acommoncauseofclassicdiseaseintumor-pronesyndromes?Lessonsfromtype2neurofibromatosis.AmJHumGenet1998;63:727-36.13TrofatterJA,MacCollinMM,RutterJL,MurrellJR,DuyaoMP,ParryDM,EldridgeR,KleyN,MenonAG,PulaskiK,HaaseVH,AmbroseCM,MunroeD,BoveC,HainesJL,MartuzaRL,MacDonaldME,SeizingerBR,ShortMP,BucklerAJ,GusellaJF.Anovelmoesin-ezrin-radixinlikegeneisacandidatefortheneurofibromatosis2tumorsuppressor.Cell1993;72:791-800.14RouleauGA,MerelP,LutchmanM,SansonM,ZucmanJ,MarineauC,Hoang-XuanK,DemczukS,DesmazeC,PlougastelB,PulstSM,LenoirG,BijlsmaE,FasholdR,DumanskiJ,deJongP,ParryD,EldridgeR,AuriasA,DelattreO,ThomasG.Alterationinanewgeneencodingaputativemembrane-organizingproteincausesneurofibromatosistype2.Nature1993;363:515-21.15RouleauGA,WerteleckiW,HainesJL,HobbsWJ,TrofatterJA,SeizingerBR,MartuzaRL,SuperneauDW,ConneallyPM,GusellaJF.GeneticlinkageofbilateralacousticneurofibromatosistoaDNAmarkeronchromosome22.Nature1987;329:246-8.16MacCollinMM,RameshV,JacobyLB,LouisDN,RubioMP,PulaskiK,TrofatterJA,ShortMP,BoveC,EldridgeR,ParryDM,GusellaJF.Mutationalanalysisofpatientswithneurofibromatosis2.AmJHumGenet1994;55:314-20.17BournD,CarterSA,MasonS,EvansDGR,StrachanT.Germlinemutationsintheneurofibromatosistype2tumoursuppressorgene.HumMolGenet1994;3:813-16.18MerelP,Hoang-XuanK,SansonM,BijlsmaE,RouleauG,Laurent-PuigP,PulstS,BaserM,LenoirG,SterkersJM,PhilipponJ,RescheF,MautnerVF,FischerG,HulsebosT,AuriasA,DelattreO,ThomasG.Screeningforgerm-linemutationsintheNF2gene.GenesChromCancer1995;12:117-27.19ParryDM,MacCollinMM,Kaiser-KupferMI,PulaskiK,NicholsonHS,BolestaM,EldridgeR,GusellaJF.Germ-linemutationsintheneurofibromatosis2gene:correlationswithdiseaseseverityandretinalabnormalities.AmJHumGenet1996;59:529-39.20KluweL,MautnerVF.Mosaicisminclassicalneurofibromatosis2patients.HumMolGenet1998;7:2051-5.21WuCL,ThakkerN,NearyWJ,BlackG,LyeR,RamsdenRT,ReadAP,EvansDGR.Differentialdiagnosisoftype2neurofibromatosis:moleculardiscriminationofNF2andsporadicvestibularschwannomas.JMedGenet1998;35:973-7.22WallaceAJ.Combinedsinglestrandconformationpolymorphismandheteroduplexanalysis.In:TaylorGR,ed.LaboratorymethodsforthedetectionofmutationsandpolymorphismsinDNA.BocaRaton:CRCPress,1997:79-94.23WeissenbachJ,GyapayG,DibC,VignalA,MorissetteJ,MillasseauP,VaysseixG,LathropM.Asecondgenerationlinkagemapofthehumangenome.Nature1992;359:794-801.PotentialofNF2inpatientswithearlyonsettumours321www.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from 24BournD,StrachanT.HighlypolymorphicdinucleotiderepeatattheNF2gene.HumGenet1995;95:712.25MarineauC,BaronC,DelattreO,ZucmanJ,ThomasG,RouleauGA.DinucleotiderepeatpolymorphismattheD22S268locus.HumMolGenet1993;2:336.26GyapayG,MorissetteJ,VignalA,DibC,FizamesC,MillasseauP,MarcS,BernardiG,LathropM,WeissenbachJ.The1993-94Genethonhumangeneticlinkagemap.NatGenet1994;7:246-339.27SchulerGD,BoguskiMS,StewartEA,SteinLD,GyapayG,RiceK,WhiteRE,RodriguezTomeP,AggarwalA,BajorekE,BentolilaS,BirrenBB,ButlerA,CastleAB,ChiannilkulchaiN,ChuA,CleeC,CowlesS,DayPJ,DiblingT,DrouotN,DunhamI,DupratS,EastC,HudsonTJ.Agenemapofthehumangenome.Science1996;274:540-6.28SkinnerHA.Theoriginofacousticnervetumours.BrJSurg1929;16:440-63.29MartuzaRL,OjemannRG.Bilateralacousticneuromas:clinicalaspects,pathogenesisandtreatment.Neurosurgery1982;10:1-12.30Zucman-RossiJ,LegoixP,DerSarkissianH,CheretG,SorF,BernardiA,CazesL,GiraudS,OllagnonE,LenoirG,ThomasG.NF2geneinneurofibromatosistype2patients.HumMolGenet1998;13:2095-101.31JacobyLB,MacCollinMM,LouisDN,MohneyT,RubioMP,PulaskiK,TrofatterJA,KleyN,SeizingerBR,RameshV,GusellaJF.ExonscanningformutationoftheNF2geneinschwannomas.HumMolGenet1994;3:413-19.32KluweL,BayerS,BaserME,HazimW,HaaseW,FunstererC,MautnerVF.IdentificationofNF2germlinemutationsandcomparisonwithneurofibromatosis2phenotypes.HumGenet1996;98:534-8.33RiccardiVM,EichnerJE.Neurofibromatosis:phenotype,naturalhistoryandpathogenesis.Baltimore:JohnsHopkinsUniversityPress,1986:178-80.34SaeedSR,WoolfordTJ,RamsdenRT,LyeRH.Magneticresonanceimaging:acost-effectivefirstlineinvestigationindetectionofvestibularschwannomas.BrJNeurosurg1995;9:497-503.7ECHO.................................................................................................................WhenHFEgenemutationdoesn’tmakesenseIronaccumulationandprogressofliverdiseaseinchronichepatitisCinfectionarenotduetoHFEmutation,sayThorburnetalfromastudyofScottishpatients.Chronicinfectionresultsinironbuildupinserumandtheliver,withliverﬁbrosis.Ironoverloadintheliverandﬁbrosisarecommontoheredi-taryhaemochromatosis,whichismostlycausedbyhavinghomozygousrecessivemissensemutationsintheHFEgene—eitherCys282TyrorHis63Asp.Somereportssuggestthatthesemutationsmightunder-lieironbuildupinchronichepatitisCinfection.Thepresentconclusioncomesfromaprospectivestudywhichscreened164consecutivepatientswithchronichepatitisCinfectionforHFEmutations,markersofironaccumulationinserumandliver,sever-ityofliverdisease,andviralgenotype.SixtysevenpatientswereheterozygousforHFEmutations:26Cys282Tyr,33His63Asp,andeightCys282Tyr/His63Asp;sevenwerehomozygousforeithermutationandwereexcluded;and90hadnomutation.NoassociationbetweenHFEgenotypeandanyofthemarkersexaminedcouldbefoundwhendataforthe157patientswereanalysedstatistically.Thorburnetalwerecarefultotestthat10non-Caucasianpatientsintheirsampledidnotskewtheresults,nordidprevioustreatmentwithinter-feron,andtheyanalysedtheresultsformenandwomenseparatelyineachofthefourgenotypicgroupstoremoveeffectsofageandmenstruation.RaisedserumironconcentrationsandHFEmutationsmaybeevidentinchronichepatitisCinfection,but,seemingly,theyarenotlinked.mGut2002;50:248–252.PleasevisittheJournalofMedicalGeneticswebsite[www.jmedgenet.com]forlinktothisfullarticle.322Mohyuddin,Neary,Wallace,etalwww.jmedgenet.comgroup.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from schwannomasyoung patients with unilateral vestibular Molecular genetic analysis of the NF2 gene inRamsden, A Read, G Black and D G R EvansA Mohyuddin, W J Neary, A Wallace, C L Wu, S Purcell, H Reid, R Tdoi: 10.1136/jmg.39.5.3152002 39: 315-322 J Med Genet(cid:160) http://jmg.bmj.com/content/39/5/315Updated information and services can be found at: These include:References #BIBLhttp://jmg.bmj.com/content/39/5/315This article cites 28 articles, 9 of which you can access for free at: serviceEmail alertingbox at the top right corner of the online article. Receive free email alerts when new articles cite this article. Sign up in theCollectionsTopicArticles on similar topics can be found in the following collections  (97)Peripheral nerve disease (257)Neuromuscular disease (886)Genetic screening / counselling (630)Epidemiology (356)Clinical diagnostic tests (234)Screening (oncology) (78)Neurooncology (44)CNS cancerNoteshttp://group.bmj.com/group/rights-licensing/permissionsTo request permissions go to:http://journals.bmj.com/cgi/reprintformTo order reprints go to:http://group.bmj.com/subscribe/To subscribe to BMJ go to:group.bmj.com on June 16, 2017 - Published by http://jmg.bmj.com/Downloaded from 